Clinical Trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-06-05; most recent amendment 2026-07-16.
Status change: Active, Not Recruiting → Recruiting 2025-10-31
Status change: Recruiting → Active, Not Recruiting 2025-05-27
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06450041
Lead Sponsor New Approaches to Neuroblastoma Therapy Consortium
Collaborators: Nationwide Children's Hospital, United Therapeutics, Children's Neuroblastoma Cancer Fund
Conditions Neuroblastoma
Enrollment 62 participants
Start Date 2024-12-16
Primary Completion 2028-12 (estimated)
Study Completion 2038-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-20